Amgen 2009 Annual Report Download - page 5
Download and view the complete annual report
Please find page 5 of the 2009 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2 -
3 -
4 -
5 -
6 -
7 -
8 -
9 -
10 -
11 -
12 -
13 -
14 -
15 -
16 -
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117
-
118
-
119
-
120
-
121
-
122
-
123
-
124
-
125
-
126
-
127
-
128
-
129
-
130
-
131
-
132
-
133
-
134
-
135
-
136
-
137
-
138
-
139
-
140
-
141
-
142
-
143
-
144
-
145
-
146
-
147
-
148
-
149
-
150
-
151
-
152
-
153
-
154
-
155
-
156
-
157
-
158
-
159
-
160
-
161
-
162
-
163
-
164
-
165
-
166
-
167
-
168
-
169
-
170
-
171
-
172
-
173
-
174
-
175
-
176
-
177
-
178
-
179
-
180
 |
 |
development. It has been a long and diffi cult
road, but returns on that investment are now
in our sights for the decade ahead. Driving
innovation will continue to mean looking
outside as well as inside—as we did last year
with Cytokinetics in heart failure and Array
BioPharma in type 2 diabetes. Investing in our
pipeline and pursuing growth through strategic
partnerships and business development are
cornerstones of our strategy.
Another goal we have set this year is to
expand internationally. Over the past decade,
we have expanded our international presence
from 18 to nearly 50 countries. In so doing,
our international product sales have grown
from 10 percent to 22 percent of total product
sales. We are committed to aggressively
continue this expansion into underserved
and fast-growing markets which many see
as among the most attractive opportunities
in our sector.
Amgen operates in a diffi cult environment.
Discovering and developing innovative new
medicines is hard work. Our U.S. healthcare
system also needs reform. The percent of GDP
spent on healthcare grows inexorably and is
the highest in the world. Yet our outcomes
are no better, and in many cases, worse than
other societies and tens of millions of our fellow
citizens cannot afford insurance or care. Our
national attempt to begin to address some
of these issues was disappointing in process
and result, but we must keep trying. Amgen
will remain constructively engaged to help
address our national healthcare system
challenges and assure America remains
a place where innovation is encouraged,
protected, and rewarded.
After 30 years, Amgen remains as committed
as ever to our mission to serve patients by
developing innovative medicines to address
serious unmet medical needs. We continue
to believe that delivering against our mission
is also the very best way to serve our
stockholders. I am excited by our prospects
and Amgen is well prepared to deal with
these challenging times.
KEVIN W. SHARER
Chairman and Chief Executive Offi cer
February 15, 2010
Awards and
Recognition
■ Denosumab was named one
of TIME magazine’s Top 10
Medical Breakthroughs of 2009.
■ Amgen was honored with
two 2009 Scrip Awards,
winning for Best Overall
Pipeline and for Best New
Drug in Nplate® (romiplostim).
■ Nplate
® received the 2009
Prix Galien USA Award for
Best Biotechnology Product.
■ Amgen was among the top
10 in both Science’s 2009
Top Employers List for large
companies and The Scientist’s
2009 survey of the Best Places
to Work in Industry.
Amgen 2009 Annual Report ■ 3